vTv Therapeutics Inc. (VTVT) — Financial statements
Income statement, balance sheet, and cash flow for vTv Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 1 | 0.00↓100.0% | 2↓49.6% | 4 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00↓100.0% | 1 | 0.00↓100.0% | 2↓49.6% | 4 | |
| Operating Expenses | ||||||
| R&D Expenses | 18↑54.7% | 12↓15.1% | 14↑10.0% | 12↓7.3% | 13 | |
| General & Administrative Expenses | 15↑9.5% | 14↑14.6% | 12↓2.4% | 12↓1.2% | 12 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 15↑9.5% | 14↑14.6% | 12↓2.4% | 12↓1.2% | 12 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 33↑30.2% | 25↓1.2% | 26↑3.8% | 25↓4.3% | 26 | |
| Total Costs & Expenses | 33↑30.2% | 25↓1.2% | 26↑3.8% | 25↓4.3% | 26 | |
| Operating Results | ||||||
| Operating Income | -33↓35.7% | -24↑5.2% | -26↓13.1% | -23↓4.1% | -22 | |
| Depreciation & Amortization | 0.02↓82.0% | 0.09↓1.1% | 0.09↓2.2% | 0.09↑3.4% | 0.09 | |
| EBITDA | -31↓37.9% | -23↑12.9% | -26↓4.4% | -25↓41.4% | -18 | |
| EBIT | -31↓37.5% | -23↑12.9% | -26↓4.4% | -25↓41.2% | -18 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↑19.1% | 2↑241.0% | 0.46↑36.2% | 0.34↑3163.6% | -0.01 | |
| Interest Income | 2↑19.5% | 2↑231.6% | 0.47↑34.1% | 0.35↑35100.0% | 0.00 | |
| Interest Expense | 0.01 | 0.00↓100.0% | 0.01↓13.3% | 0.02↑25.0% | 0.01 | |
| Non-Operating Income | -2↓10.1% | -2↓449.2% | 0.45↓80.5% | 2↑157.1% | -4 | |
| Other Income / Expenses | 2↑9.7% | 2↑439.4% | -0.46↑80.1% | -2↓157.7% | 4 | |
| Income Before Tax | -31↓37.5% | -23↑12.9% | -26↓4.4% | -25↓41.2% | -18 | |
| Income Tax Expense | 0.00↓100.0% | 0.10 | 0.00↓100.0% | 0.20↑73.9% | 0.12 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -31↓36.9% | -23↑12.6% | -26↓3.6% | -25↓41.4% | -18 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -27↓46.1% | -18↑8.8% | -20↓5.7% | -19↓47.6% | -13 | |
| Bottom-Line Net Income | -27↓46.1% | -18↑8.8% | -20↓5.7% | -19↓47.6% | -13 | |
| EPS (Basic) | -3.20↑0.0% | -3.20↑67.0% | -9.71↑2.7% | -9.98↓20.4% | -8.29 | |
| EPS (Diluted) | -3.20↑0.0% | -3.20↑67.0% | -9.71↑2.7% | -9.98↓20.4% | -8.29 | |
| Weighted Average Shares | 8↑46.0% | 6↑176.8% | 2↑8.6% | 2↑22.6% | 2 | |
| Weighted Average Diluted Shares | 8↑46.0% | 6↑176.8% | 2↑8.6% | 2↑22.6% | 2 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.